Where are you?
To give you the most accurate information about our products and what we can do for you, we need to direct you to the right site.
MagnetOs for predictable fusions
current % rate of non-unions.1,2
current % rate of revision surgeries needed.3
% fusion rate that can be improved by choosing the most effective bone graft.2,4,5
A bone graft like no other
MagnetOs isn’t like other bone grafts. It grows bone even in soft tissue thanks to our unique NeedleGrip™ surface technology which provides traction for our body’s vitally important ‘pro-healing’ immune cells (M2 macrophages).*†6,7
This in turn, unlocks previously untapped potential to stimulate stem cells – and form new bone throughout the graft.*8-10
The growing body of science behind NeedleGrip is called osteoimmunology. But for surgeons and their patients it means one thing: a more efficient and predictable fusion.*‡10
MagnetOs:
the evidence
MagnetOs is proven to be equivalent to the gold standard of autograft for spinal fusions.8-10 It has been used in more than 15,000 successful spinal fusion surgeries to date, and is supported by an unprecedented blend of scientific, pre-clinical and clinical studies through Project Fusion: our global research program, where science and clinical evidence meet.
Kuros is the first and only company to reliably translate evidence from benchtop through to patient. Watch these 5 videos to see how.
What surgeons are saying about MagnetOs
Want to learn more about MagnetOs?
Book your own appointment with one of our scientific experts.
Suggested Reading
References And Disclaimers
1. Medtech 360 report “Orthopedic Biomaterials Market Analysis 2017”.
2. Hsu, et al. GSJ. 2012;2:239–248.
3. Mabud, et al. Clin Spine Surg. 2017;30:E1376–E1381.
4. Chun, et al. Neurosurgical Focus. 2015;39(4):E10.
5. Morris, et al. ESJ. 2018;27:1856–1867.
6. Duan, et al. eCM. 2019;37:60-73.
7. Van Dijk, et al. JOR Spine . 2018;e1039.
8. Van Dijk, et al. J Biomed Mater Res. Part B: Appl Biomater. 2019;107(6):2080-2090.
9. Van Dijk, et al. eCM. 2021;41:756-73.
10. Van Dijk, et al. Clin Spine Surg. 2020;33(6):E276-E287.
*Results from in vivo laboratory testing may not be predictive of clinical experience in humans. For important safety and intended use information please visit kurosbio.com.
†MagnetOs is not cleared by the FDA or TGA as an osteoinductive bone graft.
‡MagnetOs has been proven to generate more predictable fusions than two commercially available alternatives in an ovine model of posterolateral fusion.
PROMO/KUR/GL/062-21/R02